Progress of Research on Biomarkers in Predicting Efficacy of Anti-tumor Necrosis Factor-α Monoclonal Antibody in Treatment of Inflammatory Bowel Disease
10.3969/j.issn.1008.7125.2022.01.008
- Author:
Jiahui TIAN
1
;
Chenjing XU
1
;
Hongjie ZHANG
1
Author Information
1. Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University
- Publication Type:Journal Article
- Keywords:
Biological Markers;
Colitis;
Crohn Disease;
Inflammatory Bowel Disease;
Therapy;
Tumor Necrosis Factor-alpha;
Ulcerative
- From:
Chinese Journal of Gastroenterology
2022;27(1):42-46
- CountryChina
- Language:Chinese
-
Abstract:
Anti-tumor necrosis factor (T N F) - α monoclonal antibody is a first-line treatment for inflammatory bowel disease, and its therapeutic response has attracted more and more attention. Although therapeutic drug monitoring and antidrug antibody monitoring have been widely used in clinic, however, there are no laboratory indicators that can predict the therapeutic response to anti-TNF-α before the drug treatment, so as to provide a guidance of selecting therapeutic drug. Studies have shown that some baseline biomarkers can predict the therapeutic response to anti-TNF-α. This article reviewed the progress of research on biomarkers in predicting efficacy of anti-TNF-α monoclonal antibody in treatment of inflammatory bowel disease.
